analyz
incid
risk
factor
occurr
invas
aspergillosi
ia
among
consecut
recipi
allogen
hematopoiet
sct
reducedintens
condit
regimen
allor
twentyseven
patient
develop
ia
median
day
rang
postallor
incid
confid
interv
multivari
analysi
risk
factor
develop
ia
steroid
therapi
moderatetosever
graft
vs
host
diseas
gvhd
hazard
ratio
hr
p
occurr
lower
respiratori
tract
infect
lrti
respiratori
viru
rv
hr
cmv
diseas
hr
p
variabl
decreas
surviv
allor
advanc
diseas
phase
hr
p
steroid
therapi
moderatetosever
gvhd
hr
develop
chronic
gvhd
hr
occurr
lrti
rv
hr
cmv
diseas
hr
p
wherea
occurr
ia
effect
surviv
p
result
show
ia
common
infecti
complic
allor
occur
late
posttranspl
may
strong
effect
surviv
import
observ
possibl
role
lrti
convent
rv
risk
factor
ia
invas
fungal
infect
ifi
recogn
caus
morbid
mortal
patient
undergon
allogen
hematopoiet
sct
allohsct
use
reducedintens
condit
ric
regimen
may
chang
incid
time
distribut
ifi
seen
allohsct
regard
invas
aspergillosi
ia
far
common
ifi
institut
mani
other
ric
regimen
may
chang
epidemiolog
studi
descript
risk
factor
analysi
ia
larg
patient
cohort
long
followup
report
find
regard
incid
risk
factor
develop
ia
among
adult
patient
underw
allohsct
ric
allor
hospit
de
la
santa
creu
sant
pau
barcelona
catalonia
es
prospect
monitor
occurr
ia
time
period
symptomat
patient
also
monitor
respiratori
viru
infect
allow
analysi
possibl
associ
occurr
ia
two
hundr
nineteen
consecut
adult
receiv
allor
base
fludarabin
plu
intermediatedos
bu
melphalan
divis
detail
patient
characterist
shown
tabl
patient
includ
seri
consecut
allor
trial
design
patient
elig
convent
highdos
myeloabl
condit
report
elsewher
detail
patient
gave
written
inform
consent
inclus
studi
studi
approv
nation
local
ethic
committe
brief
two
ric
regimen
use
includ
fludarabin
plu
either
oral
bu
mgkg
pharmakokinet
drugdos
adjust
iv
melphalan
mgm
myeloid
lymphoid
malign
respect
alemtuzumab
antithymocyt
globulin
given
recipi
hlamismatch
relat
donor
volunt
unrel
donor
vud
graftvshost
diseas
gvhd
prophylaxi
consist
csa
plu
shortcours
mtx
csa
plu
mycophenol
mofetil
mmf
describ
elsewher
antifung
prophylaxi
hospit
patient
high
risk
ia
kept
area
positivepressur
higheffici
particul
airfilt
isol
antiaspergillu
antifung
prophylaxi
routin
use
patient
mucos
risk
invas
candidiasi
receiv
fluconazol
prophylaxi
mgday
thu
patient
receiv
prophylact
antifung
activ
mold
earli
preengraft
period
engraft
gvhd
occur
requir
highdos
steroid
patient
receiv
antifung
prophylaxi
consist
fluconazol
itraconazol
depend
patient
toler
potenti
drug
interact
patient
requir
hospit
sever
steroidrefractori
gvhd
receiv
prophylact
therapi
lipid
formul
amphotericin
b
dose
mgkg
daili
monitor
aspergillosi
respiratori
viral
infect
aspergillosi
initi
diagnost
workup
febril
neutropen
patient
use
empir
antibacteri
treatment
follow
intern
guidelin
followup
includ
daili
clinic
examin
microbiolog
radiolog
examin
clinic
indic
empir
antifung
therapi
antimold
activ
agent
start
patient
persist
recurr
fever
unknown
origin
h
thorac
computer
tomographi
ct
scan
carri
report
earlier
patient
gvhd
febril
ill
respiratori
symptom
resolv
antibiot
also
routin
studi
chest
ct
sinc
routin
studi
galactomannan
gm
platelia
assay
biorad
laboratori
marr
la
coquett
franc
blood
sampl
sinc
maximum
three
time
per
week
inpati
visit
outpati
respiratori
sampl
also
alway
studi
fungaldirect
cytolog
stain
fungal
cultur
patient
develop
pulmonari
infect
possibl
filament
mold
fungal
origin
maintain
prospect
registri
continu
updat
senior
author
rm
respiratori
viru
rv
infect
sinc
inpati
outpati
adult
hematolog
malign
includ
hsct
recipi
sign
symptom
upper
respiratori
tract
infect
urti
lower
rti
lrti
underw
detail
virolog
evalu
patient
symptom
urti
underw
nasopharyng
aspir
npa
wherea
patient
lrti
underw
bronchoalveolar
lavag
bal
clinic
possibl
patient
pneumonia
sign
urti
undergo
npa
clinic
sampl
test
viral
ag
indirect
immunofluoresc
assay
respiratori
syncyti
viru
rsv
parainfluenza
virus
influenza
b
flua
flub
adenovirus
adv
sampl
alway
cultur
virus
plu
enteroviru
test
reversetranscript
pcr
rtpcr
nonpolio
enteroviru
describ
elsewher
addit
aliquot
bal
npa
sampl
store
test
retrospect
metapneumovirus
coronavirus
describ
detail
elsewher
definit
definit
ia
proven
probabl
ia
defin
european
organ
research
treatment
cancermycos
studi
group
consensu
respiratori
virus
aspergillosi
allogen
hsct
r
martino
et
al
guidelin
brief
probabl
ia
defin
posit
result
serum
galactomannan
optic
posit
galactomannan
bal
fluid
isol
aspergillu
sp
nonsteril
site
bal
one
sampl
sputum
two
sampl
histologicallydefin
hyalohyphomycosi
without
confirmatori
cultur
associ
suggest
clinic
radiolog
sign
suggest
radiolog
find
includ
presenc
nodul
halo
sign
neutropenia
cavit
nodul
neutrophil
recoveri
chest
xray
ct
scan
respiratori
viru
rv
infect
urti
defin
new
onset
nasal
pharyng
laryng
irrit
isol
rv
npa
lrti
defin
new
onset
cough
rale
andor
wheez
conjunct
new
pulmonari
infiltr
case
pneumonia
identifi
chest
radiograph
chest
ct
scan
isol
rv
bal
lung
sampl
cmv
diseas
diseas
divid
pneumonia
gastro
intestin
diseas
retin
cmv
pneumonia
defin
presenc
sign
andor
symptom
pulmonari
diseas
combin
detect
cmv
bal
fluid
lung
tissu
sampl
detect
cmv
carri
viru
isol
histopatholog
test
immunohistochem
analysi
situ
hybrid
diagnosi
cmv
gastro
intestin
diseas
requir
posit
histolog
affect
segment
gastrointestin
tract
wherea
cmv
retin
defin
characterist
retin
lesion
identifi
expert
ophthalmologist
incid
develop
ia
calcul
time
transplant
use
cumul
incid
estim
consid
relaps
progress
underli
malign
death
caus
compet
event
wherea
patient
still
aliv
progressionfre
time
report
censor
last
followup
date
incid
posttranspl
event
acut
chronic
gvhd
infect
rv
also
calcul
cumul
incid
os
calcul
kaplanmei
probabl
estim
time
transplant
death
caus
censor
last
followup
survivor
univari
analys
risk
factor
develop
ia
carri
use
univari
cox
regress
analysi
wherea
logrank
test
use
os
addit
character
truli
relev
risk
factor
multivari
test
carri
multivari
cox
regress
analysi
includ
variabl
univari
test
variabl
analyz
effect
develop
ia
os
shown
tabl
posttranspl
variabl
use
steroid
moderatetosever
gvhd
defin
acut
gvhd
grade
iiiv
andor
extens
chronic
gvhd
cmv
infect
cmv
diseas
presenc
monocytopenia
l
occurr
urti
lrti
rv
includ
timedepend
covari
assumpt
proport
hazard
time
test
explanatori
covari
use
timedepend
covari
report
p
valu
twosid
signific
level
use
statist
analys
carri
twentyseven
patient
develop
probabl
proven
ia
postallor
two
patient
met
criteria
possibl
ia
death
postmortem
examin
confirm
diagnosi
note
case
nonaspergillu
invas
fungal
infect
cumul
incid
ia
confid
interv
ci
median
day
onset
infect
postallor
rang
nine
case
start
day
posttranspl
wherea
nine
occur
day
addit
nine
case
day
aspergillu
speci
isol
case
consist
aspergillu
fumigatu
flavu
terreu
aspergillu
niger
case
includ
sinc
galactomannan
index
blood
andor
bal
posit
n
addit
n
microbiolog
criteria
diagnosi
ia
univari
multivari
risk
factor
ia
shown
tabl
multivari
model
three
signific
variabl
associ
higher
risk
develop
ia
use
steroid
therapi
moderatetosever
gvhd
hazard
ratio
hr
p
figur
occurr
cmv
diseas
posttranspl
hr
ci
p
figur
occurr
lrti
rv
hr
ci
figur
variabl
analyz
timedepend
variabl
thu
event
occur
onset
ia
consid
risk
factor
ia
patient
steroid
begun
occurr
ia
median
time
interv
start
steroid
therapi
onset
ia
rang
day
variabl
durat
neutropenia
variabl
shown
tabl
significantli
affect
risk
ia
respect
durat
neutropenia
median
day
reach
stabl
neutrophil
count
l
rang
occur
case
day
addit
nine
delay
engraft
beyond
day
prolong
pancytopenia
graft
failur
year
posttranspl
cumul
incid
aspergillosi
figur
fouryear
cumul
incid
develop
invas
pulmonari
aspergillosi
accord
need
steroid
therapi
moderatetosever
graftversushost
diseas
p
valu
refer
multivari
cox
regress
analysi
includ
variabl
timedepend
covari
thin
line
refer
patient
receiv
steroid
dark
line
receiv
steroid
tabl
patient
develop
least
one
episod
lrti
rv
develop
ia
rv
infect
median
interv
day
rang
day
patient
receiv
least
three
day
one
system
therapi
antimold
activ
antifung
agent
voriconazol
case
caspofungin
case
lipid
formul
amphotericin
b
case
surviv
onset
ia
patient
analyz
surviv
accord
presenc
five
poor
risk
factor
surviv
recent
publish
allogen
hsct
recipi
ia
monocytopenia
l
dissemin
aspergillosi
renal
failur
time
upper
limit
normal
uln
elev
bilirubin
time
uln
respiratori
failur
requir
supplement
oxygen
maintain
mmhg
progress
advanc
statu
underli
malign
surviv
patient
risk
factor
respect
os
estim
patient
ia
compar
control
patient
develop
ia
p
multivari
analysi
develop
ia
analyz
timedepend
posttranspl
variabl
effect
os
p
variabl
predict
death
advanc
diseas
phase
hr
ci
p
steroid
therapi
moderatetosever
gvhd
hr
ci
develop
chronic
gvhd
hr
ci
occurr
lrti
rv
hr
ci
occurr
cmv
diseas
posttranspl
hr
ci
p
also
analyz
effect
develop
ia
nonrelaps
mortal
nrm
cumul
incid
nrm
whole
group
ci
factor
associ
higher
nrm
multivari
analysi
acut
gvhd
grade
iiiv
hr
ci
p
poor
perform
statu
hr
ci
p
occurr
cmv
diseas
hr
ci
p
occurr
lrti
rv
hr
ci
p
develop
ia
analyz
timedepend
posttranspl
variabl
effect
nrm
univari
analysi
patient
ia
compar
control
patient
develop
ia
p
studi
repres
one
largest
epidemiolog
studi
occurr
invas
mycos
allor
case
ia
occur
without
singl
case
nonaspergillu
mold
invas
yeast
infect
studi
focus
ia
addit
long
followup
detail
prospect
observ
case
lend
credibl
result
first
surpris
lack
ia
earli
posttranspl
period
period
first
group
neutropeniarel
ia
tradit
observ
possibl
short
durat
neutropenia
low
nonhematolog
toxic
respons
earli
protect
ia
even
without
use
antiaspergillu
drug
prophylaxi
howev
longer
followup
risk
develop
ia
still
substanti
similar
incid
ia
tradit
observ
allohsct
convent
myeloabl
condit
review
publish
median
time
onset
ia
total
nearli
allohsct
procedur
day
rang
day
emphas
late
onset
case
ia
studi
compar
incid
ia
studi
import
rememb
mani
studi
kaplanmei
p
estim
method
use
analyz
p
posttranspl
event
least
one
clear
compet
event
howev
recommend
method
cumul
incid
estim
take
account
major
compet
event
case
relaps
underli
diseas
compet
event
occurr
ia
use
studi
nearli
alway
incid
posttranspl
event
occurr
ia
significantli
lower
probabl
event
calcul
typic
kaplanmei
method
establish
risk
factor
ia
among
allohsct
recipi
includ
durat
neutropenia
engraft
earli
posttranspl
period
case
late
graft
failur
use
durat
glucocorticosteroid
donor
type
underli
diseas
age
transplant
recipi
presenc
treatment
gvhd
studi
interest
sever
observ
close
monitor
occurr
rv
infect
symptomat
patient
abl
analyz
possibl
effect
occurr
ia
known
long
time
appar
immunocompet
least
sever
immunocompromis
patient
develop
ia
immedi
rv
lower
respiratori
tract
infect
associ
describ
mostli
influenza
infect
addit
recent
studi
two
independ
allohsct
group
report
infect
rv
influenza
viru
type
b
parainfluenza
respiratori
syncyti
viru
adenoviru
rv
independ
risk
factor
develop
ia
larg
retrospect
analys
studi
reinforc
role
rv
infect
may
develop
ia
allohsct
addit
found
lrti
increas
risk
develop
ia
wherea
isol
urti
effect
associ
may
reflect
direct
implic
alter
bronchial
mucosa
pulmonari
defens
mechan
rv
infect
howev
could
also
simpli
reflect
mechan
risk
factor
progress
urti
lrti
rv
occur
also
predispos
develop
ia
unexpectedli
occurr
cmv
diseas
need
steroid
therapi
treat
moderatetosever
agvhd
andor
cgvhd
also
identifi
multivari
analysi
risk
factor
ia
wellknown
risk
factor
effect
univari
analysi
find
import
practic
implic
highlight
allor
recipi
strategi
antiaspergillu
prophylaxi
focus
patient
requir
steroid
andor
develop
clinic
signific
gvhd
rather
neutropen
phase
procedur
ifi
current
infrequ
anoth
relev
consequ
observ
ric
regimen
allograft
may
carri
signific
risk
develop
late
onset
ia
use
prophylaxi
may
also
justifi
cmv
diseas
lrti
rv
addit
prophylaxi
also
target
patient
possibl
recent
describ
risk
factor
ia
hyperferritenemia
iron
overload
donorrecipi
genet
polymorph
may
predispos
opportunist
infect
hand
sinc
introduct
fluconazol
prophylaxi
risk
develop
sever
invas
candidiasi
posttranspl
decreas
current
incid
mortal
yeast
infect
well
allohsct
studi
confirm
studi
fourmonth
mortal
onset
ia
high
allohsct
recipi
usual
rang
similar
mortal
patient
includ
herein
interest
fact
mortal
differ
markedli
accord
risk
factor
surviv
variabl
select
identifi
three
recent
studi
analyz
prognost
variabl
surviv
patient
ia
allohsct
use
small
patient
sampl
suggest
result
may
use
clinic
practic
although
larger
valid
prognost
model
improv
studi
clearli
need
unclear
whether
high
mortal
ia
essenti
attribut
ia
may
consequ
underli
highrisk
factor
turn
increas
risk
develop
infect
thu
interest
multivari
surviv
analysi
found
ia
independ
risk
factor
die
allor
howev
owe
limit
abil
identifi
truli
independ
risk
factor
surviv
complex
clinic
situat
believ
observ
interpret
caution
studi
shown
patient
develop
ia
poor
month
surviv
howev
recent
result
seattl
group
show
surviv
ia
improv
patient
receiv
ric
regimen
respect
receiv
convent
myeloabl
condit
addit
sever
opportunist
infect
well
known
coexist
possibl
involv
mortal
mani
patient
thu
probabl
cmv
diseas
lrti
rv
coexist
ia
time
death
make
difficult
interpret
main
caus
death
hand
find
lrti
rv
strong
effect
os
lend
support
continu
effort
analyz
epidemiolog
clinic
effect
infect
allohsct
recipi
includ
virolog
studi
routin
posttranspl
workup
patient
urti
lrti
conclus
ia
import
caus
infecti
morbid
allor
although
occur
late
posttranspl
may
strong
effect
surviv
import
observ
possibl
role
lrti
convent
rv
risk
factor
ia
author
declar
conflict
interest
